Onderzoeker
Stephanie Du Four
- Trefwoorden:Geneeskunde
Affiliaties
- Neuroprotectie & Neuromodulatie (Onderzoeksgroep)
Lid
Vanaf12 mei 2023 → Heden - Neurochirurgie (Departement)
Lid
Vanaf2 nov 2021 → Heden - Neurochirurgie (Departement)
Lid
Vanaf2 nov 2021 → 13 feb 2022 - Neurochirurgie (Departement)
Lid
Vanaf1 aug 2016 → 31 okt 2021 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf6 aug 2015 → 27 jan 2016 - Neurologie (Departement)
Lid
Vanaf1 aug 2015 → 31 jul 2016 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf23 okt 2014 → 30 apr 2020 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 jan 2014 → 31 jul 2015 - Neurochirurgie (Departement)
Lid
Vanaf1 jan 2013 → 31 jul 2015 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf14 sep 2011 → 6 jun 2014 - Laboratorium voor Moleculaire en Cellulaire Therapie (Onderzoeksgroep)
Lid
Vanaf1 sep 2011 → 19 mrt 2021 - Fysiologie (Departement)
Lid
Vanaf1 sep 2011 → 31 dec 2013 - Neurologie (Departement)
Lid
Vanaf1 aug 2011 → 31 dec 2012 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf23 aug 2007 → 8 jul 2011
Publicaties
11 - 20 van 26
- Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion(2016)
Auteurs: Stephanie Du Four, Sarah Maenhout, Daphné Benteyn, Brenda De Keersmaecker, Johnny Duerinck, Kris Thielemans, Bart Neyns, Joeri L Aerts
Pagina's: 727-740 - Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells(2016)
Auteurs: Sandra Van Lint, Dries Renmans, Katrijn Broos, Lode Goethals, Sarah Maenhout, Daphné Benteyn, Cleo Goyvaerts, Stephanie Du Four, Kevin Van Der Jeught, Lukasz Bialkowski, et al.
Pagina's: 146-156 - Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma(2016)
Auteurs: Johnny Duerinck, Stephanie Du Four, Fenne Vandervorst, Nicky D'haene, Marie Le Mercier, Alex Michotte, A Vanbinst, Hendrik Everaert, I. Salmon, F Bouttens, et al.
Pagina's: 147-155 - Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs(2016)
Auteurs: Stephanie Du Four, Sarah Maenhout, Simone P Niclou, Kris Thielemans, B Neyns, Joeri L Aerts
Pagina's: 2514-2531 - Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma(2015)
Auteurs: Stephanie Du Four, Wilhelm Sander, Peter Hau
Pagina's: 5551-5557 - Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model(2015)
Auteurs: Stephanie Du Four, Sarah Maenhout, Kari De Pierre, Dries Renmans, Simone P Niclou, Kris Thielemans, Bart Neyns, Joeri L Aerts
Pagina's: e998107 - AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells(2014)
Auteurs: Sarah Maenhout, Stephanie Du Four, Jurgen Corthals
Pagina's: 6801-6815 - Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients(2014)
Auteurs: Stephanie Du Four, Angela Hong, Matthew Chan, Michail Charakidis, Johnny Duerinck, Sofie Wilgenhof, Wei Wang, Linda Feng, Alex Michotte, Meena Okera, et al.
- Ipilimumab in patients with melanoma brain metastases, a single-center experience in an expanded access program.(2013)Volume: 30
Auteurs: Stephanie Du Four, A. Seghers
Pagina's: 19027Aantal pagina's: 1 - Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.(2013)
Auteurs: Stephanie Du Four, I. Salmon, D. Lienard, V.d. Marmol
Pagina's: 215-222